Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw

Sanford Baim, Paul D. Miller

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Bone turnover markers (BTMs) have become increasingly important in the management of postmenopausal osteoporosis (PMO). In bisphosphonate-treated women with PMO, BTMs can provide early indications of treatment efficacy, are predictors of BMD response and fracture risk reduction, and are potentially useful for monitoring patient compliance. The bone resorption marker serum C-telopeptide crosslink of type 1 collagen (sCTX) has shown high sensitivity and specificity for the detection of increased bone resorption. Recently, sCTX has been singled out as a potential indicator of risk of osteonecrosis of the jaw (ONJ) in patients receiving oral bisphosphonates who require oral surgery. However, whether BTMs are capable of predicting ONJ risk and whether sCTX is usable for this purpose are controversial questions. This article presents an overview of the current literature regarding critical issues affecting the clinical utility of BTMs (including variability and reference ranges) and the current applications of BTMs in PMO management, with a focus on sCTX. Last, the appropriateness of using sCTX to predict ONJ risk in women receiving oral bisphosphonates for PMO is evaluated.

Original languageEnglish
Pages (from-to)561-574
Number of pages14
JournalJournal of Bone and Mineral Research
Volume24
Issue number4
DOIs
StatePublished - Apr 1 2009

Fingerprint

Postmenopausal Osteoporosis
Osteonecrosis
Bone Remodeling
Jaw
Diphosphonates
Serum
Bone Resorption
Fracture Fixation
Oral Surgery
Risk Reduction Behavior
Patient Compliance
Collagen Type I
Reference Values
Biomarkers
Sensitivity and Specificity

Keywords

  • Bisphosphonates
  • Bone resorption
  • Bone turnover markers
  • Osteonecrosis of the jaw
  • Osteoporosis

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. / Baim, Sanford; Miller, Paul D.

In: Journal of Bone and Mineral Research, Vol. 24, No. 4, 01.04.2009, p. 561-574.

Research output: Contribution to journalArticle

@article{6976b22644ba43f9ad3ea006fe5cc50f,
title = "Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw",
abstract = "Bone turnover markers (BTMs) have become increasingly important in the management of postmenopausal osteoporosis (PMO). In bisphosphonate-treated women with PMO, BTMs can provide early indications of treatment efficacy, are predictors of BMD response and fracture risk reduction, and are potentially useful for monitoring patient compliance. The bone resorption marker serum C-telopeptide crosslink of type 1 collagen (sCTX) has shown high sensitivity and specificity for the detection of increased bone resorption. Recently, sCTX has been singled out as a potential indicator of risk of osteonecrosis of the jaw (ONJ) in patients receiving oral bisphosphonates who require oral surgery. However, whether BTMs are capable of predicting ONJ risk and whether sCTX is usable for this purpose are controversial questions. This article presents an overview of the current literature regarding critical issues affecting the clinical utility of BTMs (including variability and reference ranges) and the current applications of BTMs in PMO management, with a focus on sCTX. Last, the appropriateness of using sCTX to predict ONJ risk in women receiving oral bisphosphonates for PMO is evaluated.",
keywords = "Bisphosphonates, Bone resorption, Bone turnover markers, Osteonecrosis of the jaw, Osteoporosis",
author = "Sanford Baim and Miller, {Paul D.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1359/jbmr.090203",
language = "English",
volume = "24",
pages = "561--574",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw

AU - Baim, Sanford

AU - Miller, Paul D.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Bone turnover markers (BTMs) have become increasingly important in the management of postmenopausal osteoporosis (PMO). In bisphosphonate-treated women with PMO, BTMs can provide early indications of treatment efficacy, are predictors of BMD response and fracture risk reduction, and are potentially useful for monitoring patient compliance. The bone resorption marker serum C-telopeptide crosslink of type 1 collagen (sCTX) has shown high sensitivity and specificity for the detection of increased bone resorption. Recently, sCTX has been singled out as a potential indicator of risk of osteonecrosis of the jaw (ONJ) in patients receiving oral bisphosphonates who require oral surgery. However, whether BTMs are capable of predicting ONJ risk and whether sCTX is usable for this purpose are controversial questions. This article presents an overview of the current literature regarding critical issues affecting the clinical utility of BTMs (including variability and reference ranges) and the current applications of BTMs in PMO management, with a focus on sCTX. Last, the appropriateness of using sCTX to predict ONJ risk in women receiving oral bisphosphonates for PMO is evaluated.

AB - Bone turnover markers (BTMs) have become increasingly important in the management of postmenopausal osteoporosis (PMO). In bisphosphonate-treated women with PMO, BTMs can provide early indications of treatment efficacy, are predictors of BMD response and fracture risk reduction, and are potentially useful for monitoring patient compliance. The bone resorption marker serum C-telopeptide crosslink of type 1 collagen (sCTX) has shown high sensitivity and specificity for the detection of increased bone resorption. Recently, sCTX has been singled out as a potential indicator of risk of osteonecrosis of the jaw (ONJ) in patients receiving oral bisphosphonates who require oral surgery. However, whether BTMs are capable of predicting ONJ risk and whether sCTX is usable for this purpose are controversial questions. This article presents an overview of the current literature regarding critical issues affecting the clinical utility of BTMs (including variability and reference ranges) and the current applications of BTMs in PMO management, with a focus on sCTX. Last, the appropriateness of using sCTX to predict ONJ risk in women receiving oral bisphosphonates for PMO is evaluated.

KW - Bisphosphonates

KW - Bone resorption

KW - Bone turnover markers

KW - Osteonecrosis of the jaw

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=65549102548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549102548&partnerID=8YFLogxK

U2 - 10.1359/jbmr.090203

DO - 10.1359/jbmr.090203

M3 - Article

C2 - 19257812

AN - SCOPUS:65549102548

VL - 24

SP - 561

EP - 574

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 4

ER -